Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges

  • Despite significant advances made by modern medicine, universal access to healthcare is still arguably the single largest unmet medical need
  • Sandoz “HACk” – Healthcare Access Challenge – is a competition seeking young people with innovative ideas to “reimagine” access to healthcare
  • Sandoz HACk is partnering with OpenIDEO – a global community that drives collaboration, innovation and impact around the world’s toughest problems

Holzkirchen, September 28, 2016 – Sandoz, the Novartis generic and biosimilar …

/by

Top-line results for PF-06438179 (biosimilar infliximab) demonstrate equivalent efficacy to reference product

  • Sandoz, a Novartis division, the pioneer and global leader in biosimilars acquired the rights from Pfizer for the development, commercialization and manufacture of PF-06438179 in the 28 countries that form the European Economic Area (EEA)* in February 2016 where it is known as GP1111.
  • The confirmatory study (REFLECTIONS B537-02), evaluating the efficacy, safety and immunogenicity of PF-06438179 (biosimilar infliximab) to reference product Remicade® (infliximab), met its primary endpoint.
  • Results demonstrate equivalent efficacy as measured by the American College of …
/by